AYTU BIOPHARMA, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-6.5% -$1M
$15M
Cost of Revenue↑+2.0% +$106K
$6M
Gross Profit↓-10.8% -$1M
$10M
R&D↓-100.0% -$522K
$0
SG&A
—
D&A↑+0.0% +$0
$100K
Operating Income↓-16.2% -$275K
$-2M
EBITDA↓-17.2% -$275K
$-2M
Interest Expense↓-48.1% -$519K
$560K
Other Income/Expense↓-355.2% -$11M
$-8M
Pretax Income↓-2870.7% -$11M
$-11M
Tax Provision↑+100.0% +$283K
$0
Net Income↓-1443.1% -$11M
$-11M
Gross Margin↓-3.0pts
63.5%
Operating Margin↓-2.5pts
-13.0%
Net Margin↓-74.7pts
-69.8%
Effective Tax Rate↑+74.1pts
0.0%
Deferred Tax Liabilities
—
ETR (Continuing Operations)↑+17.4pts
-3.2%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-8.9pts
-0.2%
Operating Lease Cost
—
Revenue YoY Variation↑+7.0pts
-6.5%
Income YoY Variation↑+137.7pts
-16.2%
Revenue QoQ Variation↑+11.3pts
9.2%
Income QoQ Variation↑+51.3pts
-31.0%